Lumos Diagnostics Holdings
Lumos Diagnostics Holdings specializes in the development, manufacture, and distribution of point-of-care diagnostic tests and associated readers. The company is positioned as a leader in rapid diagnostics, offering unique solutions like FebriDx, which aids in differentiating bacterial from viral infections at the point of care.
Short position
Lumos Diagnostics Holdings (ASX:LDX) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 5,059 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.87% in June 2022. LDX is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Lumos Diagnostics Holdings (LDX) company profile
Profile, insiders and operations
Company
AI-generated research profile of Lumos Diagnostics Holdings
LDX intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links